Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Clinicopathological study of 113 gastrointestinal stromal tumors.

Bhalgami R, Manish K, Patil P, Mehta S, Mohandas KM.

Indian J Gastroenterol. 2013 Jan;32(1):22-7. doi: 10.1007/s12664-012-0273-2. Epub 2012 Dec 8.

PMID:
23224791
2.

[Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].

Zhang L, Cai M, Deng J, Wang X, Wang B, Liu N, Pan Y, Zhang R, Cui Q, Liang H.

Zhonghua Wei Chang Wai Ke Za Zhi. 2014 Apr;17(4):331-4. Chinese.

PMID:
24760639
3.
4.

Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.

Cao H, Zhang Y, Wang M, Shen DP, Sheng ZY, Ni XZ, Wu ZY, Liu Q, Shen YY, Song YY.

Chin Med J (Engl). 2010 Jan 20;123(2):131-6.

PMID:
20137358
5.

Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.

Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, Cao H, Zhang ZG.

BMC Gastroenterol. 2014 Jun 7;14:105. doi: 10.1186/1471-230X-14-105.

6.

Gastrointestinal stromal tumors: diagnosis and treatment.

Acín-Gándara D, Pereira-Pérez F, Castaño-Pascual A, Durán-Poveda M, Antequera-Pérez A, Miliani-Molina C.

Cir Cir. 2012 Jan-Feb;80(1):44-51.

PMID:
22472152
7.

Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.

Pandey R, Kochar R.

J Gastrointest Cancer. 2012 Dec;43(4):547-52. doi: 10.1007/s12029-012-9423-0. Review.

PMID:
22847491
8.

Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.

Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T.

Digestion. 2013;87(1):47-52. doi: 10.1159/000343938. Epub 2013 Jan 21.

9.

Presentation and management of gastrointestinal stromal tumours.

Mongan AM, Malik V, Rowley S, Claxton Z, Muldoon C, O'Toole D, Ravi N, Reynolds JV.

Ir Med J. 2013 Jun;106(6):176-9.

PMID:
23909154
10.

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.

DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.

Ann Surg. 2013 Sep;258(3):422-9. doi: 10.1097/SLA.0b013e3182a15eb7.

11.

[Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].

Li SX, Li ZY, Zhang LH, Bu ZD, Wu AW, Wu XJ, Zong XL, Shan F, Ji X, Ji JF.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Mar;16(3):226-9. Chinese.

PMID:
23536340
12.

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.

Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.

J Med Econ. 2013 Sep;16(9):1106-19. doi: 10.3111/13696998.2013.819357. Epub 2013 Jul 19.

PMID:
23808902
13.

[New prospective on adjuvant treatment for gastrointestinal stromal tumors].

Pan ZZ, Wu XJ.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Mar;16(3):212-5. Chinese.

PMID:
23536337
14.

Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.

Søreide K, Sandvik OM, Søreide JA, Gudlaugsson E, Mangseth K, Haugland HK.

Clin Transl Oncol. 2012 Aug;14(8):619-29. doi: 10.1007/s12094-012-0851-x. Epub 2012 Jul 18.

PMID:
22855146
15.

Gastrointestinal stromal tumors (GIST): a single center experience.

Kostka R, Gürlich R, Koldová L.

Acta Chir Belg. 2012 Jan;112(1):33-9.

PMID:
22442907
16.

Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.

Jiang WZ, Guan GX, Lu HS, Yang YH, Kang DY, Huang HG.

J Surg Oncol. 2011 Dec;104(7):760-4. doi: 10.1002/jso.22010. Epub 2011 Jun 28.

PMID:
21713778
17.

Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.

Cohen MH, Johnson JR, Justice R, Pazdur R.

Oncologist. 2012;17(7):992-7. doi: 10.1634/theoncologist.2012-0109. Epub 2012 May 29.

18.

The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.

Li Y, Meng X.

Ann R Coll Surg Engl. 2015 Apr;97(3):215-20. doi: 10.1308/003588414X14055925061432.

19.

[Prognosis analysis of 216 cases of gastrointestinal stromal tumor].

Liu LC, Xu WT.

Zhonghua Wei Chang Wai Ke Za Zhi. 2012 Mar;15(3):255-8. Chinese.

PMID:
22454172
20.

[A multicentre retrospective cohort study of patients with gastrointestinal stromal tumors in Shandong Province].

Ning L, Yan W, Zhang M, Gong H, Dai Y, Jiang L, Lin H, Zhang D, Zhou Y.

Zhonghua Wei Chang Wai Ke Za Zhi. 2014 Apr;17(4):326-30. Chinese.

PMID:
24760638

Supplemental Content

Support Center